Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

Inge Verbrugge1, Jim Hagekyriakou2, Leslie L. Sharp3, Mara Galli1, Alison West1, Nicole M. McLaughlin2, Hélène Duret2, Hideo Yagita6, Ricky W. Johnstone1,4, Mark J. Smyth2,4, and Nicole M. Haynes1,4

Abstract

It is becoming increasingly evident that radiotherapy may benefit from coincident or subsequent immunomodulation. In this study, we examined whether the antitumor effects of radiotherapy, in established triple-negative breast tumors could be enhanced with combinations of clinically relevant monoclonal antibodies (mAb), designed to stimulate immunity [anti-(α)-CD137, α-CD40] or relieve immunosuppression [α-programmed death (PD)-1]. While the concomitant targeting of the costimulatory molecules CD137 and CD40 enhanced the antitumor effects of radiotherapy and promoted the rejection of subcutaneous BALB/c-derived 4T1.2 tumors, this novel combination was noncurative in mice bearing established C57BL/6-derived AT-3 tumors. We identified PD-1 signaling within the AT-3 tumors as a critical limiting factor to the therapeutic efficacy of α-CD137 therapy, alone and in combination with radiotherapy. Strikingly, all mice bearing established orthotopic AT-3 mammary tumors were cured when α-CD137 and α-PD-1 mAbs were combined with single- or low-dose fractionated radiotherapy. CD8+ T cells were essential for curative responses to this combinatorial regime. Interestingly, CD137 expression on tumor-associated CD8+ T cells was largely restricted to a subset that highly expressed PD-1. These CD137 PD-1High CD8+ T cells persisted in irradiated AT-3 tumors, expressed Tim-3, granzyme B and Ki67 and produced IFN-γ ex vivo in response to phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulation. Notably, radiotherapy did not deplete, but enriched tumors of functionally active, tumor-specific effector cells. Collectively, these data show that concomitant targeting of immunostimulatory and inhibitory checkpoints with immunomodulatory mAbs can enhance the curative capacity of radiotherapy in established breast malignancy. Cancer Res; 72(13); 3163–74. ©2012 AACR.
anticancer regimens is likely required. Indeed, we and others have shown that combining mAbs targeting CD40, CD14, and/or CD137, designed to modulate DC and T-cell activity, respectively, are highly effective, particularly in combination with TRAIL-receptor agonists and histone deacetylase inhibitors (HDACi) in eradicating established solid tumors (15–17). However, given the intrinsic resistance of many tumors to TRAIL-receptor agonists and HDACi, as well as the fact that TRAIL-receptor agonists are still in clinical development and the applicability of HDACi is currently largely restricted to hematologic malignancies, the broader application of these combinations is presently limited (18, 19). Blockade of immune checkpoint-inhibitory molecules such as CTLA-4 or programmed death (PD)-1, alone or in combination with anti-αCD137 therapy also increased the therapeutic activity of vaccine approaches and α-erbB2 therapy (20, 21). To date however, the therapeutic benefit of targeting multiple immune stimulatory and/or inhibitory pathways in combination with radiotherapy has not been described.

Here, we show that mAbs to CD137, CD40, and PD-1, which are all in clinical development, combined with single- and low-dose fractionated radiotherapy, induced the rejection of established subcutaneous and orthotopically implanted, triple-negative [estrogen receptor (ER)−, Her2/neu− and progesterone receptor (PR)−] AT-3 and 4T1.2 mammary tumors. These results are encouraging, given the unmet medical need to treat triple-negative breast cancer in the clinic, as they do not respond to endocrine treatment and other currently available targeted agents. Importantly, we identified the key innate and adaptive immune cells critical to the antitumor effects of radioimmunotherapy. These cells expressed CD137 and/or PD-1 and persisted within the irradiated tumors. This study provides strong validation for combining radiotherapy with immunotherapy and justifies the therapeutic application of both immunostimulatory and checkpoint-inhibitory mAbs as adjuvants to radiotherapy in breast cancer treatment.

Materials and Methods

Mice

Six- to 12-week-old C57BL/6 (B6) and BALB/c mice were obtained from The Walter and Eliza Hall Institute of Medical Research (WEHI) or Animal Resource Centre (Perth, Western Australia). All mice were maintained under specific pathogen-free conditions and used in accordance with institutional guidelines of the Peter MacCallum Cancer Centre.

Cell lines

BALB/c-derived 4T1.2 (22) and B6-derived AT-3 (23) mammary carcinoma cell lines were obtained from Dr Robin Anderson in 2005 and Dr. Trina Stewart in 2007 (Peter MacCallum Cancer Centre, VIC, Australia). Both cell lines were periodically authenticated by morphologic inspection and tested negative for Mycoplasma contamination by PCR tests in 2009 to 2010. AT-3 cells, retrovirally transduced to stably express ovalbumin (OVA) were generated as described (24). AT-3 cells were cultured at 37°C, 10% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM), 10% FBS, 0.1 mmol/L nonessential amino acids, 1 mmol/L sodium pyruvate, 2 mmol/L l-glutamine. 4T1.2 cells were cultured at 37°C, 5% CO2 in RPMI-1640, 10% FBS, 100 μg/ml penicillin/streptomycin, 2 mmol/L l-glutamine.

Cell death and clonogenic assays

For cell death assays, tumor cells were incubated with 10 μmol/L qVD (InSolution Q-VD-OPh; Calbiochem) or corresponding dimethyl sulfoxide (DMSO) concentrations for 30 minutes. Cells were subsequently treated with 0 to 30 Gy ionizing radiation (IR; 137Cs source; at an absorbed dose rate of ~0.6 Gy/min) and harvested 24 to 48 hours post-treatment. Flow cytometry was used to measure (i) cell death by Annexin-V/PI staining and (ii) apoptosis by caspase-3 cleavage as described (25). Clonogenic assays were essentially conducted as described (26). Briefly, cells were plated at increasing densities of up to 8,000 cells/10-cm dish. After adhering 4–6 hours at 37°C, cells were irradiated (0–10 Gy). After 8 to 11 days of incubation under normal culture conditions, cells were stained with 2.5% glutaraldehyde and 0.05% crystal violet for more than 15 minutes at room temperature. Colonies (>40 cells) were counted using an inverted microscope and clonogenicity of untreated cells (0 Gy) was set to 100%.

TUNEL staining

Mice bearing 20 to 25 mm2 subcutaneous AT-3 tumors were mock-irradiated or treated with 12 Gy radiotherapy. Tumors from control and irradiated mice (n = 3) were dissected 16, 24, and 48 hours post-radiotherapy and processed for immunohistochemical analyses [hematoxylin and eosin (H&E) and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining]. Fixed and paraffin-embedded tissues were randomly sectioned and stained for apoptotic cells using an ApopTag Peroxidase In Situ Apoptosis Detection Kit (Chemicon International) as per manufacturers’ instructions. Metamorph Imagin Program Series 7.6.3 was used to quantify single, tumor cell–specific TUNEL-positive events (Zeiss Microscope; Carl Zeiss; objective: ×10/0, 30 Plan-Neofluar).

Phenotyping of tumor cells and tumor-infiltrating lymphocytes

Expression of PD-L1 on in vitro cultured and explanted tumor cells, before and 12 to 96 hours postradiation treatment (0–30 Gy in vitro; 12 Gy in vivo) was assessed by flow cytometry as described (27) using biotinylated α-mouse CD274 (PD-L1, BD Pharmingen) mAb and allophycocyanin (APC)-conjugated streptavidin (eBioscience). CD45.2 (eBioscience) staining of explanted tumor samples distinguished leukocytes from tumor cells.

Analysis of tumor-infiltrating leukocytes was conducted before and 16, 36, and 84 hours post-radiotherapy (12 Gy, 5–18 mice/group) for surface expression of CD137 (17B8; eBioscience), PD-1 (J43; eBioscience), CD44 (IM7; BD Pharmingen), CD62L (MEL-14; eBioscience), Tim-3 (RMT3-23; eBioscience), and OVA-tetramer (KoOVA₂₅⁷-2₆⁴-PE; obtained from S.J. Turner, Department of Microbiology and Immunology, University of Melbourne, Parkville, VIC, Australia).
Intracellular staining for granzyme B (mouse-anti-human granzyme B; BD Bioscience) and Ki67 (mouse-anti-human Ki67; BD Bioscience) was carried out using a Cytofix/CytoPerm, Fixation/Permeabilization Solution Kit according to the manufacturers’ instructions (BD Bioscience). Spleens from tumor-bearing mice served as background staining controls. Cell viability was assessed using DAPI (4',6-diamidino-2-phenylindole; Invitrogen) or propidium iodide (PI) and cells were analyzed on a CantoII or LSRII analyzer (BD Biosciences).

Staining for intracellular IFN-γ following phorbol 12-myristate 13-acetate and ionomycin stimulation

Uninjected, established (20–25 mm²) orthotopic AT-3 tumors (n = 7) were harvested and processed into single-cell suspensions. Whole-cell preparations were plated at 3 × 10⁵ cells/200 μL DMEM/2% fetal calf serum (FCS) in a 96-well U-bottom plate. Cells were treated with 50 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma Aldrich) and 1 μg/mL ionomycin (Sigma Aldrich). Control (unstimulated) wells were treated with an equal volume of DMSO. GolgiPlug (1 μg/mL; BD Biosciences) was added to all wells before incubating the cultures for 4 hours at 37°C, 5% CO₂. Staining for intracellular IFN-γ in CD45.2⁺PD-1⁻low and PD-1⁺high CD8⁺ T cells was carried out as described earlier for granzyme B and Ki67 detection and analyzed on a LSRII analyzer.

Therapeutic antibodies and reagents

The rat mAb to mouse CD137 (3H3, IgG2a) was generated in house as described (28) and protein-G purified or purchased from BioXCell. The rat α-mouse CD40 mAb (FKG4.5, IgG2a) was from WEHI. The rat α-mouse PD-1 mAb (RMP1-14, IgG2a) was prepared as described (29). Depleting antibodies to asialoGM1 (natural killer [NK] cells; Wako Pure Chemical), mouse CD4 (GK1.5), and CD8β (53–5; BioXCell) were prepared as described (30). For both therapy and depletion studies, MAC4 mAb was used as the isotype control (28).

Therapy of transplanted tumors

Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) or isoflurane and injected with 4T1.2 (5 × 10⁶/50 μL PBS) or AT-3 (1 × 10⁶/50 μL PBS) tumors subcutaneously on the right hind leg or orthotopically into the fourth mammary fat pad. Tumor size was measured every 2 to 3 days using electronic calipers and represented as tumor area (length × width). Radioimmunotherapy commenced when tumors reached 20 to 25 mm². Mice were divided into groups of 4 to 7. Irradiation of subcutaneous tumors was conducted essentially as described (31). Briefly, for irradiation of subcutaneous tumors, mice were injected into perspex jigs and the tumor bearing leg isolated and restrained for exposure to a single dose of radiation (12 Gy). To minimize exposure of normal tissue to radiotherapy, mice were protected by a 3-mm thick lead shield containing 1.5 cm² holes; permitting exposure of the leg to radiotherapy. For irradiation of orthotopic tumors, mice were anesthetized with ketamine/xylazine and positioned under a lead shield containing 0.8 cm² exposure holes. Irradiation was delivered using a 6-MeV electron beam at a dose rate of 20 Gy/min (Varian Medical Systems) as a 12 Gy single fraction or in 4 fractions of 4 or 5 Gy at 24-hour intervals. Control mice were placed in radiation jigs (subcutaneous tumors) or anesthetized (orthotopic tumors), but not exposed to radiotherapy.

Immunotherapy consisted of α-CD137 (100 μg) and/or α-CD40 (100 μg), α-PD-1 (100 μg), or MAC4 (100μg) mAbs, administered intraperitoneally on days 0, 4, 8, and 12 relative to radiotherapy. Antibodies depleting CD4⁺ (100 μg) or CD8β⁺ (50 μg) T cells were administered intraperitoneally on days −1, 0, then every 4 days until day 40, α-asialo GM1 (100 μg) was administered intraperitoneally on days −1, 0, then every 6 days until day 40 relative to radioimmunotherapy.

All radioimmunotherapeutic combinations and treatment regimes were well-tolerated. Mice were sacrificed when tumors reached 100 to 200 mm².

Statistics

Statistical differences between groups were analyzed with unpaired Student t tests (experiments not involving mice) or Mann–Whitney U tests using GraphPad Prism (GraphPad Software).

Results

Ionizing radiation induces cell death in triple-negative mammary tumor cells

In vitro assay systems were initially used to screen the BALB/c-derived 4T1.2 and C57BL/6-derived AT-3 triple-negative mammary tumor lines for their sensitivity to ionizing radiation. Radiation-induced cell death as determined by Annexin-V/PI staining was evident in both cell lines and occurred in a time- and dose-dependent manner (Fig. 1A and B, top). In 4T1.2 cells, radiation-induced cell death was not affected by the pan-caspase inhibitor qVD (Fig. 1A) or overexpression of the antiapoptotic protein Bcl-2 (data not shown). In addition, caspase-3 cleavage was not detected in irradiated 4T1.2 cultures (data not shown); collectively indicating that apoptosis was not the primary mechanism of radiation-induced cell death in contrast, caspase-3 cleavage was detected in irradiated AT-3 cultures (Fig. 1B). Overexpression of Bcl-2 (data not shown) or treatment with qVD (Fig. 1B, top) significantly reduced Annexin-V/PI staining, indicating that apoptosis contributed to radiation-induced AT-3 cell death. Despite these mechanistic differences the radiosensitivity of 4T1.2 and AT-3 tumor cells, as determined in long-term clonogenic assays, was comparable (Fig. 1C).

These findings were subsequently confirmed in a neoadjuvant setting of established disease, where a single dose of 12 Gy radiotherapy induced a comparable degree of tumor growth delay in subcutaneous 4T1.2 and AT-3 tumors, without inducing complete regression (Supplementary Fig. S1). TUNEL analysis revealed higher levels of radiotherapy-induced apoptosis in AT-3 than in 4T1.2 tumors in vivo [Fig. 1D, (4T1.2)-E (AT-3)]. A modest (<2-fold) but statistically significant increase in the number of apoptotic events, compared with mock treatment was detected 24 hours after radiotherapy in 4T1.2 tumors (Fig. 1D). Whereas in the AT-3 tumors, at 16 hours post-radiotherapy a >10-fold increase in TUNEL⁺ events, compared
with mock treatment was observed (Fig. 1E). Importantly, despite differences in the biologic response to radiotherapy, the radioresponsiveness of the 4T1.2 and AT-3 tumors was comparable.

**Therapeutic targeting of PD-1 but not CD40 enhanced the curative capacity of radiotherapy/a-CD137 treatment in AT-3 tumors**

Previously, we showed that a-CD137/a-CD40 therapy enhanced the antitumor activity of HDACi or a-DR5 therapy in tumor cells that possessed functional apoptotic pathways, suggesting that drug-induced apoptosis engaged antitumor immune responses that could be enhanced with antibody-based immunotherapy (15, 16). On the basis of these results and the ability of radiotherapy to induce apoptosis in AT-3 tumors, we initially analyzed novel radioimmunotherapeutic combinations in AT-3 mammary tumors. We first examined whether a-CD137/a-CD40 therapy could be effectively combined with radiotherapy to control and eradicate subcutaneous AT-3 tumors. Predetermined doses of a-CD40 and/or...
α-CD137 mAbs were used alone (Fig. 2A, top) or in combination with radiotherapy (12 Gy; Fig. 2A, bottom). Anti-CD137 therapy, alone or in combination with α-CD40 treatment significantly enhanced radiotherapy-induced growth inhibition of AT-3 tumors (Fig. 2A). However, tumors grew out in all mice (Fig. 2A). Although a percentage (40%) of tumor-bearing mice were found to be highly responsive to radiotherapy and α-CD40 treatment (Fig. 2A), α-CD40 therapy did not further enhance the therapeutic response of AT-3 tumors to radiotherapy/α-CD137 treatment (Fig. 2A). Interestingly, however, in established subcutaneous 4T1.2 tumors radiotherapy/α-CD40/α-CD137 therapy was found to be curative in >80% of mice (Supplementary Fig. S2A). The antitumor effects of this triple combination in 4T1.2 tumors were critically dependent on CD8+ T and NK cells (Supplementary Fig. S3A), which expressed CD137 (Supplementary Fig. S3B) and could induce immunologic memory capable of controlling the outgrowth of a secondary tumor challenge (Supplementary Fig. S2). Importantly, these findings show that this novel radioimmunotherapy has the potential to eradicate established, triple-negative mammary tumors.

Given the inability of radiotherapy/α-CD137/α-CD40 treatment to eradicate AT-3 tumors, tumor cell–associated factors that might inhibit the development of an effective antitumor immune response were examined. One candidate was the checkpoint-inhibitory ligand, programmed death-ligand 1 (PD-L1) that has been reported to inhibit T-cell activation on PD-1+ expressing T cells, by blocking interleukin (IL)-2 production following TCR stimulation (32). Interestingly, while PD-L1 expression was not detected on in vitro cultured AT-3 cells (Fig. 3A, left), explanted AT-3 tumors expressed PD-L1 (Fig. 3A, right), which was unaffected by radiotherapy. On the basis of these observations we examined the therapeutic activity of an antagonistic α-PD-1 mAb in combination with radiotherapy and α-CD137 treatment. While α-PD-1 therapy had no single-agent activity, nor did it enhance the response of AT-3 tumors to radiotherapy (Fig. 3B), α-PD-1 treatment significantly enhanced the responsiveness of AT-3 tumors to radiotherapy/α-CD137 therapy, achieving a rejection rate of up to 40% (Fig. 3B and C). These combined effects were lost in mice depleted of CD8+ T cells and significantly affected by depletion of NK cells (Fig. 3D), but unaffected by depletion of CD4+ T cells (Fig. 3D). Importantly, in mice cured of primary tumors, the outgrowth of secondary AT-3 tumors was significantly impaired, indicating the establishment of immunologic memory (Fig. 3E). Taken together, these data suggest that PD-1 signaling within AT-3 tumors limited the capacity of α-CD137/α-CD40 immunotherapy to support the immunoadjuvant properties of radiotherapy and that inhibition of PD-1 signaling was, therefore, required to optimally promote CD8+ T cell and NK cell function to reject AT-3 tumors.

**Rejection of orthotopic AT-3 tumors with radiotherapy/α-CD137/α-PD-1 therapy**

We next determined whether α-CD137/α-PD-1 therapy promoted the rejection of irradiated AT-3 tumors in the physiologically relevant tissue microenvironment of the mammary fat pad. Notably, orthotopic AT-3 tumors expressed PD-L1 at levels similar to subcutaneous tumors (data not shown). Combined effects were observed with radiotherapy and
Figure 3. Rejection of established subcutaneous AT-3 tumors with radiotherapy and α-CD137/α-PD-1 mAbs. A, surface expression of PD-L1 on live, in vitro cultured AT-3 tumor cells and explanted, live CD45.2/C0 AT-3 tumor cells, before (narrow line) and at the indicated time points post (bold line) IR. Isotype controls 0 Gy: solid histogram, dashed histogram: 12 Gy. B, AT-3 tumor-bearing mice were treated with 12 Gy radiotherapy (bottom) or mock-irradiated (top) in combination with α-CD137 and/or α-PD-1 mAbs as indicated. Individual tumor growth curves (gray lines) and mean tumor growth (black line) are shown. C, mean tumor sizes in each group in B at day 28 post-tumor inoculation. *P < 0.05; **P < 0.01; and ***P < 0.001. D, AT-3 tumor-bearing mice were treated with cIg (Ctr) or depleting antibodies to CD4, CD8β, or asialoGM1 before mock irradiation and MAC4 (Ctr), or radioimmunotherapy.
α-Cd137, α-PD-1, and α-Cd137/α-PD-1 therapy (Fig. 4A and B). Strikingly, up to a 100% rejection rate was achieved when radiotherapy was combined with both α-Cd137 and α-PD-1 mAbs. Consistent with our observations in subcutaneous AT-3 tumors, α-Cd137 therapy showed single-agent activity, whereas α-PD-1 treatment did not. However, α-PD-1 treatment prolonged the therapeutic response of orthotopic AT-3 tumors to α-Cd137 therapy and significantly enhanced the antitumor effect of radiotherapy in a small percentage of mice (Fig. 4A and B). These results reaffirm the importance of PD-1 as a possible immunotherapeutic target in breast cancer.

Characterization of a persistent CD137⁺PD-1<sup>High</sup>CD8⁺ T-cell subset in irradiated AT-3 tumors

Given the profound therapeutic efficacy of α-Cd137/α-PD-1 therapy in irradiated AT-3 tumors, we next examined the AT-3 tumor-associated lymphocytes for expression of CD137 and PD-1. We focused on the characterization of CD8⁺ T cells as they accounted for more than 40% of the tumor-associated CD45.2⁺ cells (44.8% ± 3%; 20–25 mm² control tumor, n = 7) and were the primary mediators of the antitumor activity of radiotherapy/α-Cd137/α-PD-1 therapy in subcutaneous AT-3 tumors (Fig. 3D). Interestingly, CD137 expression was only detected on a subset of PD-1<sup>High</sup>-expressing CD8⁺ T cells (Fig. 5A). The majority of CD8⁺ T cells in AT-3 tumors expressed low levels of PD-1 and were negative for CD137 (Fig. 5A). Notably, CD137 and PD-1 expression was also observed on tumor-associated NK and CD4⁺ T cells (data not shown). Of the PD-1⁺-expressing CD8⁺ T cells, the PD-1<sup>Low</sup> subset was most affected by radiotherapy. Indeed the frequency of cells within the PD-1<sup>Low</sup> population was significantly reduced post-radiotherapy, resulting in a temporary enrichment of the PD-1<sup>High</sup>/CD137⁺ population of CD8⁺ T cells (Fig. 5A) and an increased ratio of PD-1<sup>High</sup> to PD-1<sup>Low</sup> cells in tumors at 12 hours post-radiotherapy (Fig. 5B).

Further characterization of the tumor-associated PD-1<sup>High</sup> and PD-1<sup>Low</sup> subsets revealed that both were CD44⁺ and CD62L⁻ (data not shown), two hallmarks of an activated T-cell phenotype. However, expression of the activation marker CD44 was highest on the PD-1<sup>High</sup> subset, indicative of a more antigen-experienced population (Fig. 5C). In support of this, expression of the immune regulatory molecule T-cell immunoglobulin mucin (Tim)-3, which has been linked to TCR engagement and proliferation (33) was also found to be tightly

Figure 3. Continued. [radiotherapy/α-Cd137/α-PD-1 mAbs, (IR + IT)]. Results represent mean tumor growth ± SEM. Differences between growth curves in the radioimmunotherapy-treated groups are indicated: control versus CD8 T-cell depletion (from day 23 post-tumor inoculation); **, P < 0.01; control versus NK cell depletion (days 23, 26, 33, 37, and 49); *, P < 0.05; (days 30, 35, 40, 42, 44, 46); ***, P < 0.01. E, left, tumor-free, IR/α-Cd137/α-PD-1–treated mice were rechallenged with 10⁶ AT-3 cells (gray lines) >80 days after primary AT-3 tumor clearance. Growth of secondary subcutaneous tumor inocula were assessed against primary AT-3 tumor growth in naive B6 mice (black lines). Right, mean tumor sizes in naive and cured mice at day 50 post-tumor inoculation. * *, P = 0.013. Results are pooled data from 2 independent experiments. B, D, and E, numbers in parentheses indicate the fraction of tumor-free mice 40 days post-tumor inoculation.

Figure 4. Rejection of established orthotopic AT-3 tumors with radiotherapy and α-Cd137/α-PD-1 mAbs. A, mice bearing orthotopic AT-3 tumors were treated with 12 Gy radiotherapy (bottom) or mock-irradiated (top) in combination with α-Cd137 and/or α-PD-1 mAbs as indicated. Individual tumor growth curves (gray lines) and mean tumor growth (black line) are shown. Numbers in parentheses indicate the fraction of tumor-free mice 40 days post-tumor inoculation. **, P < 0.01.
associated with this PD-1^{High} subset (Fig. 5C). Notably, radiotherapy did not alter the expression status of either of these molecules on the PD-1^{High} and PD-1^{Low} CD8\(^+\) T-cell subsets (Fig. 5C). Assessment of their proliferative status by Ki67 staining showed that both PD-1^{High} and PD-1^{Low}-expressing cell populations were actively proliferating (Fig. 5D). Ki67 staining was highest in the PD-1^{High} subset and was unaffected by radiotherapy. In contrast, Ki67 expression within the PD-1^{Low} CD8\(^+\) T-cell population increased at 36 hours post-radiotherapy (Fig. 5E). Further to this, the PD-1^{High} and PD-1^{Low} CD8\(^+\) T-cell subsets were equally capable of producing IFN-\(\gamma\) in response to PMA and ionomycin (Fig. 5F), suggesting that both were functionally active \(\text{ex vivo}\). Importantly, these functionally responsive populations of CD137\(^+\)CD8\(^+\) T cells persisted post-radiotherapy, highlighting the fact that radiotherapy does not deplete, but can enrich tumors for critical effector cells, capable of driving immune responses to dying tumor cells.

**Tumor specificity is associated with PD-1\(^{High}\)/CD137\(^+\) CD8\(^+\) T cells**

To investigate whether radiotherapy enriched AT-3 tumors for tumor-reactive CD8\(^+\) T cells, we examined the
Radioimmunotherapy in Established Mammary Cancer

Figure 6. Antigen specificity of CD137+PD-1High and PD-1Low CD8+ T cells. A, mice bearing orthotopic OVA-expressing AT-3 tumors were treated with radiotherapy. CD45.2+CD8+ tumor-infiltrating T cells in explanted AT-3 tumors were analyzed and contour plots generated as described for Fig. 5A (n = 6-18 mice/group). The concatenated frequency of CD45.2+PD-1Low and CD45.2+PD-1High CD8+ T cells is shown for each time point in each group. B, ratio of CD45.2+CD8+PD-1High/CD45.2+CD8+PD-1Low cells in control and irradiated tumors analyzed in A at all indicated time points. **, P < 0.01. C, flow cytometric plots showing OVA tetramer staining within PD-1High and PD-1Low CD8+ T-cell populations from mice analyzed in A. Spleen from tumor-bearing mice served as background staining control.

Although our data so far highlight the therapeutic potential of radioimmunotherapy for the treatment of breast cancer, in the clinic, patients typically receive a series of low-dose fractionated treatments of radiotherapy to limit normal tissue toxicity. We therefore examined whether concomitant targeting of CD137 and PD-1 could reduce established orthotopic AT-3 tumors treated with fractionated radiotherapy. Certainly this approach seemed viable given that single-dose 12 Gy radiotherapy did not deplete the AT-3 tumors of CD137+CD8+ T cells. On the basis of the clonogenic survival curve in Fig. 1C, mice were treated with 4 fractions of 4 Gy, achieving a dose close to 12 Gy, or 4 fractions of 5 Gy. Anti-CD137–PD-1 therapy in combination with either 4 × 4 Gy or 4 × 5 Gy was more effective in controlling tumor outgrowth than either treatment alone; achieving rejection rates of 40% and 80%, respectively (Fig. 7A and B). The finding that antibody-based immunotherapy enhanced the antitumor response to low-dose fractionated radiotherapy shows the clinical potential of this radioimmunotherapeutic approach for treating established breast cancer.

**Discussion**

To our knowledge, this is the first preclinical study to examine the therapeutic impact of combining multiple stimulatory and/or inhibitory mAbs with radiotherapy and the cellular mechanisms underlying these responses in established breast cancer. We show in two distinct models of triple-negative mammary cancer that unique combinations of radioimmunotherapy are capable of curing mice of established disease. Radioimmunotherapy was well-tolerated and effective when used in a clinically relevant fractionated radiotherapy regime against orthotopically implanted tumors. The profound therapeutic efficacy of radiotherapy in combination with α-CD137/α-PD-1 therapy in established AT-3 tumors is likely linked to the capacity of radiotherapy to enrich the tumor microenvironment of critical tumor-reactive CD8+ T cells that coexpress CD137 and PD-1.

The checkpoint-inhibitory receptor PD-1 plays an important role in the regulation of immune responses and maintenance of peripheral immune tolerance (34). However, in the context of tumor immunity, the inhibitory actions of PD-1 can be deleterious to the development of robust antitumor immune responses (reviewed in ref. 35). While antibody-mediated blockade of PD-1 signaling had minimal impact on the growth of irradiated AT-3 tumors, it significantly enhanced the curative capacity of radiotherapy/α-CD137 therapy in this model; highlighting PD-1 signaling as a potential limiting factor to the therapeutic success of radioimmunotherapy. Interestingly, α-CD137/α-PD-1 therapy was equally as effective as radiotherapy in suppressing orthotopic tumor growth, highlighting the
capacity of α-CD137/α-PD-1 mAbs to re-engage the antitumor activity of tumor-associated lymphocytes. Consistent with this, CD137 expression on AT-3 tumor-associated CD8⁺ T cells, which were critical for the antitumor activity of radiotherapy/α-CD137/α-PD-1, was restricted to a PD-1High expressing subset. These CD137⁺ PD-1HighCD8⁺ T cells also expressed the immune regulatory molecule Tim-3. The coexpression of PD-1 and Tim-3 has been associated with an exhausted T-cell phenotype (36). However, the similarities between the PD-1HighTim3⁺ and PD-1LowTim3⁻CD8⁺ T-cell populations in terms of IFN-γ production, proliferative status and cytolytic potential, suggests that the PD-1HighCD8⁺ T-cell subset is not an exhausted population but comprises of terminally differentiated, antigen-responsive cells. Interestingly, in mice bearing OVA-expressing AT-3 tumors, all tumor-associated OVA-tetramer⁺CD8⁺ T cells coexpressed CD137 and PD-1. While endogenous AT-3 antigens and antigen-specific CD8⁺ T cells have yet to be characterized, these results strongly suggest that tumor-specific CD8⁺ T cells reside within the tumor-associated CD137⁺ PD-1High subset and thus could be the primary targets of α-CD137/α-PD-1 therapy.

The temporary enrichment of PD-1High CD8⁺ T cells in irradiated AT-3 tumors and concomitant loss of PD-1Low-expressing CD8⁺ T cells is intriguing and further favors the PD-1High-expressing cells as immunotherapeutic targets of α-PD-1 therapy. The reasons for the differential responsiveness of PD-1High⁺ and PD-1Low-expressing CD8⁺ T-cell subsets to radiotherapy are still unclear. However, it is tempting to speculate, based on their CD44HighCD62L⁻ phenotype that the antigen-experienced PD-1High subset comprises of more committed or terminally differentiated tumor-specific T cells and thus are more radioresistant. Indeed, studies have reported the acquisition of radioresistance by T cells upon encountering tumor antigen in vivo (37). Furthermore, within the PD-1LowCD8⁺ T-cell pool, a population of suppressor T cells may exist, which are characteristically more radiosensitive than other T cells (38, 39). Alternatively, radiotherapy may promote a more rapid and/or preferential recruitment of antigen-experienced PD-1High T cells into the tumor microenvironment than “nonspecific” or newly engaged tumor-reactive CD8⁺ T cells.

In 4T1.2 tumors, which in contrast to the AT-3 model, supported a necrotic core (Supplementary Fig. S4) and died in response to radiotherapy in a nonapoptotic manner, α-PD-1 therapy alone was sufficient to reject irradiated tumors (Supplementary Fig. S5). These data suggest that the inflammatory nature of the tumor microenvironment can impact upon the potency of radioimmunotherapy. In line with this, while
radiotherapy/α-CD137/α-CD40 therapy was noncurative in established subcutaneous AT-3 tumors, this novel combination increased the survival rate achieved with radiotherapy alone by greater than 70% in 4T1.2 tumors. These results are significant given the high metastatic potential of these tumors (40) and show the immunogenic nature of nonapoptotic radiation-induced cell death (reviewed in refs. 41, 42).

Given the efficacy of α-CD137 therapy in irradiated AT-3 and 4T1.2 tumors, we predicted that antibody-based targeting of other costimulatory receptors might mediate similar therapeutic effects. The CD137 family member OX40 has been reported to enhance CD8+ T-cell–dependent antitumor effects of radiotherapy in highly immunogenic OVA-expressing Lewis lung carcinoma and MCA205 sarcoma (8, 43) and was therefore of particular interest. Surprisingly however, α-OX40 therapy did not enhance the therapeutic efficacy of radiotherapy in 4T1.2 (Supplementary Fig. S6A) and AT-3 tumors (Supplementary Fig. S6B). The reasons for the lack of α-OX40 activity in these models remain unresolved; however α-CD137 therapy can also directly alter expression of adhesion molecules on tumor endothelial tissue, which can in turn promote infiltration of activated T cells (44). It is therefore possible that other factors before or post-radiotherapy, account for the different levels of α-CD137 and α-OX40 mAb activity in 4T1.2 and AT-3 tumors.

In summary, we found that single-dose and fractionated radiotherapy can be safely and effectively combined with multiple immunostimulatory and/or -inhibitory mAbs to cure mice of established triple-negative mammary tumors. Importantly, functionally responsive, tumor-reactive lymphocytes, expressing clinically viable immunologic targets such as CD137 and/or PD-1 persisted within irradiated tumors. Collectively, these results provide strong validation for combining radiotherapy with multiple immunostimulatory and inhibitory signaling pathways in patients with breast cancer treated with neoadjuvant radiotherapy. We predict that cancers of other tissue origins, in which radiotherapy is used as the primary course of treatment, will also be responsive to such therapeutic strategies.

Disclosure of Potential Conflicts of Interest

During the preparation of the manuscript, L.L. Sharp was an employee of Pfizer and has ownership interest (including patents) for the same. No potential conflicts of interest were disclosed by other authors.

Authors’ Contributions

Conception and design: I. Verbrugge, L.L. Sharp, R.W. Johnstone, M.J. Smyth, N. M. Haynes
Development of methodology: A.C. West, H. Yagita, N.M. Haynes
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): I. Verbrugge, J. Hagekyriakou, M. Galli, A.C. West, N.M. Haynes
Analysis and interpretation of data (e.g., statistical analysis, bios-statistics, computational analysis): I. Verbrugge, M. Galli, A.C. West, M.J. Smyth, N.M. Haynes
Writing, review, and/or revision of the manuscript: I. Verbrugge, J. Hagekyriakou, L.L. Sharp, H. Yagita, R.W. Johnstone, M.J. Smyth, N.M. Haynes
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Hagekyriakou, N.M. McLaughlin, H. Duret, H. Yagita, M.J. Smyth
Study supervision: L.L. Sharp, R.W. Johnstone, M.J. Smyth, N.M. Haynes

Acknowledgments

The authors thank Susan Jackson and Rachel Walker for technical assistance.

Grant Support

This work was financially supported by the Dutch Cancer Society to I. Verbrugge (NK2009-4446). National Health and Medical Research Council of Australia (NHMRC) program grants, Susan G. Komen Breast Cancer Foundation, Victorian Cancer Agency (to M.J. Smyth and R.W. Johnstone); Victorian Breast Cancer Research Consortium (to R.W. Johnstone, M.J. Smyth, and N.M. Haynes); Leukemia Foundation of Australia, Australian Rotary Health Foundation (to R.W. Johnstone); an NHMRC Fellowship (to N.M. Haynes); and the Cancer Australia grant (to N.M. Haynes). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 25, 2012; revised April 22, 2012; accepted April 22, 2012; published OnlineFirst May 8, 2012.

References


Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

Inge Verbrugge, Jim Hagekyriakou, Leslie L. Sharp, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-0210

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/05/08/0008-5472.CAN-12-0210.DC1

Cited articles
This article cites 44 articles, 25 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/13/3163.full.html#ref-list-1

Citing articles
This article has been cited by 22 HighWire-hosted articles. Access the articles at:
/content/72/13/3163.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.